Intraoperative Radiotherapy (IORT) Devices Market Global Report 2026

The intraoperative radiotherapy (IORT) devices market size has grown strongly in recent years. It will grow from $0.46 billion in 2025 to $0.5 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing cancer incidence rates, rising adoption of advanced cancer treatment procedures, growing demand for targeted radiation therapies, expansion of oncology care infrastructure, increasing clinical adoption of intraoperative treatment approaches.

The intraoperative radiotherapy (IORT) devices market size is expected to see strong growth in the next few years. It will grow to $0.7 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing preference for personalized cancer treatment, rising demand for precision radiation delivery solutions, growing adoption of mobile intraoperative radiotherapy systems, expanding integration of image-guided surgical technologies, increasing investment in advanced oncology treatment facilities. Major trends in the forecast period include increasing adoption of precise radiation delivery systems, growing integration of real-time imaging in surgical procedures, rising demand for single-session cancer treatment approaches, expansion of minimally invasive oncology treatment solutions, growing development of compact and mobile radiotherapy systems.

The rising incidence of breast cancer is expected to drive the growth of the intraoperative radiotherapy (IORT) devices market going forward. Breast cancer refers to a condition in which abnormal cells in breast tissue grow uncontrollably, forming malignant tumors that may spread to other areas of the body. The increasing incidence of breast cancer is creating demand for timely diagnosis and effective treatment approaches, accelerating the adoption of advanced therapies that enhance clinical outcomes and improve disease management. The growing number of breast cancer cases is increasing the number of patients undergoing breast-conserving surgery, thereby driving demand for intraoperative radiotherapy (IORT) devices that provide targeted radiation delivery during surgery and reduce the requirement for multiple postoperative radiotherapy sessions. For instance, in June 2026, according to the Centers for Disease Control and Prevention, a US-based federal agency, the United States reported 288,494 new cases of female breast cancer in 2023, while 43,402 women died from the disease in 2024. Therefore, the rising incidence of breast cancer is driving the growth of the intraoperative radiotherapy (IORT) devices market.

Key companies operating in the intraoperative radiotherapy (IORT) devices market are concentrating on developing advanced robotic-assisted radiation therapy platforms to improve treatment precision, streamline clinical workflows, and enhance connectivity across surgical oncology procedures. Robotic-assisted intraoperative radiotherapy platforms are advanced systems that enable highly precise radiation delivery during surgery through automated positioning, digital treatment planning, and seamless integration with hospital infrastructure. For example, in April 2025, Carl Zeiss Meditec AG, a Germany-based medical technology company, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ZEISS INTRABEAM 700, a next-generation intraoperative radiotherapy platform. The system features robotic-assisted precision, digital-first workflow architecture, integrated Radio Frequency Identification (RFID)-enabled applicator recognition, and advanced treatment planning software, supporting more accurate and efficient intraoperative radiation therapy for neuro-oncology and breast cancer procedures.

In October 2023, Elekta AB, a Sweden-based company offering radiation therapy, radiosurgery, and brachytherapy systems along with treatment planning software for cancer and neurological disorder care, acquired the Xoft brachytherapy business from iCAD Inc. for an undisclosed value. Through this acquisition, Elekta aimed to expand its intraoperative and electronic brachytherapy offerings while increasing access to advanced radiation treatment solutions across various healthcare settings by utilizing its worldwide commercial infrastructure. iCAD Inc. is a US-based medical technology company that developed the Xoft Axxent Electronic Brachytherapy (eBx) System, an electronic radiation technology platform commonly used for intraoperative radiotherapy (IORT) applications.

Major companies operating in the intraoperative radiotherapy (iort) devices market report are Carl Zeiss Meditec AG, Elekta AB, Siemens Healthineers AG, Panacea Medical Technologies Pvt. Ltd., Brainlab AG, Ion Beam Applications SA, IntraOp Medical Corporation, S.I.T. Sordina IORT Technologies S.p.A., Xstrahl Ltd, Eckert & Ziegler BEBIG GmbH, RaySearch Laboratories AB, PTW Freiburg GmbH, ORFIT Industries NV, Cablon Medical B.V., Standard Imaging Inc., LAP GmbH Laser Applications, Mirion Technologies Inc., GMV Innovating Solutions SL, CivaTech Oncology Inc., Radiation Products Design Inc.

North America was the dominant region in the intraoperative radiotherapy (IORT) devices market in 2025. Western Europe is expected to be the rapidly growing region in the forecast period. The regions covered in the intraoperative radiotherapy (IORT) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the intraoperative radiotherapy (IORT) devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.